Rankings
▼
Calendar
ICCC FY 2025 Earnings — ImmuCell Corporation Revenue & Financial Results | Market Cap Arena
ICCC
ImmuCell Corporation
$60M
FY 2025 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$28M
+4.3% YoY
Gross Profit
$11M
41.4% margin
Operating Income
$2M
6.0% margin
Net Income
-$1M
-3.8% margin
EPS (Diluted)
$-0.12
Cash Flow
Operating Cash Flow
$0
Free Cash Flow
$0
Stock-Based Comp.
$0
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$28M
$26M
+4.3%
Gross Profit
$11M
$8M
+44.1%
Operating Income
$2M
-$2M
+200.5%
Net Income
-$1M
-$2M
+51.8%
← Q4 2024
All Quarters
Q1 2025 →